cancer or cancer-associated complications and age-related ophthalmologic diseases
Founded in 2010, we are a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies. We have been forward-looking in deploying its presence in a number of promising therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology and autoimmune diseases. We also proactively established several self-developed technology platforms, such as Y-BODY®, Check-Body, Nano-Ybody®, etc., promoting the development of more candidates to clinical stages with high efficiency.
-
4Innovative Platforms
-
80 %R&D Employees
-
78Patents and patent applications
(of which 33 have been issued, and 45 applications are pending)
Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively.He also got a Doctor of Philosophy from McMaster University in November 2005.
Dr. Zhou has over 30 years of experience in the healthcare and pharmaceutical industries, he worked for a number of leading enterprise, including Schering-Plough Corporation, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.
Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology as well as a visiting professor at Central South University.
Dr. Yang Bin currently serves as the vice president of the manufacturing center of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).
Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.
Dr. Huang Shaoyi, currently serves as the senior director of the clinical center, who is responsible for the academic support of the Company's clinical projects and developing policies and management processes related to clinical research.
Dr. Huang has extensive experience in clinical research and product development. He served as the deputy director of the medical oncology department of Wuhan YZY Medical Science and Technology Co., Ltd. (武汉友芝友医疗科技股份有限公司) from March 2014 to July 2020, where he was responsible for R&D and clinical work.
He obtained a bachelor's degree in biotechnology in June 2001 and a master's degree in microbiology in December 2004 from Wuhan University (武汉大学), respectively. In August 2013, he obtained a doctorate in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center.
-
Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively.He also got a Doctor of Philosophy from McMaster University in November 2005.
Dr. Zhou has over 30 years of experience in the healthcare and pharmaceutical industries, he worked for a number of leading enterprise, including Schering-Plough Corporation, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.
Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology as well as a visiting professor at Central South University.
-
Dr. Yang Bin currently serves as the vice president of the manufacturing center of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).
Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.
-
Dr. Huang Shaoyi, currently serves as the senior director of the clinical center, who is responsible for the academic support of the Company's clinical projects and developing policies and management processes related to clinical research.
Dr. Huang has extensive experience in clinical research and product development. He served as the deputy director of the medical oncology department of Wuhan YZY Medical Science and Technology Co., Ltd. (武汉友芝友医疗科技股份有限公司) from March 2014 to July 2020, where he was responsible for R&D and clinical work.
He obtained a bachelor's degree in biotechnology in June 2001 and a master's degree in microbiology in December 2004 from Wuhan University (武汉大学), respectively. In August 2013, he obtained a doctorate in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center.
The predecessor of the Company, Wuhan YZY Biopharma Limited Company was established.
The initiation of BsAb platform development
The initiation of M802 R&D
The filing of the PCT patent application “Bispecific antibody” for the protection of the YBODY® platform
Patent protection for our YBODY® platform in U.S. expanded to cover 35 targets.
M701 became the second BsAb to file IND application in China.
M701 received China’s second IND approval for self-developed bispecific antibody.
March 2018 The establishment of the Check-BODY platform
Patent issued for the protection of M802 in China.
Patent issued for the protection of our YBODY® platform in CD3 and HER2 targets in U.S.
The establishment of the Nano-YBODY™ platform
Completed Series B Financing(1) and raised an aggregate amount of approximately RMB168.7 million.
Obtained NMPA IND approval for our clinical investigation of Y150 in rrMM in China.
Obtained FDA IND approval for our clinical investigation of Y101D for solid tumors in U.S.
Obtained NMPA IND approval for our clinical investigation of Y2019 in China
Initiated a Phase II clinical trial for M701 monotherapy in combination with systematic treatment for MA in patients with EpCAM-positive carcinomas in China.
The Company was converted into a joint stock limited company with its name changed to “Wuhan YZY Biopharma Co., Ltd.（武汉友芝友生物制药股份有限公司）
Obtained IND approval for a Phase Ib/II clinical trial of M701 for the treatment of MPE in China.
Entered into asset transfer agreement with CMS Vision for Y400.
Obtained the IND approval for a Phase Ib/II clinical trial of Y101D in combination with gemcitabine and albumin paclitaxel as the first-line treatment for pancreatic cancer patients in China
Obtained IND approval for a Phase Ib/II clinical trial of Y101D in combination with bevacizumab in treating HCC and other advanced solid tumors in China
Y332 received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA)
Y400 received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA)
-
Phone：027-82668988 -
E-Mail：info@yzybio.com -
Postcode：430075 -
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China -
Fax：027-68788819 -
Business Development Contact：BD@yzybio.com
E-Mail：info@yzybio.com
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
